Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ulrich Starke

Internal Medicine Covington, LA Medical Doctor

NPI 1114907300 CMS profile 186736

20 Starbrush Cir, Covington, LA 70433

Open in the dashboard

General payments

$6,065

356 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ulrich Starke of Covington, LA is reported in the CMS Open Payments database as having received $6,065 across 356 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $14 1
2024 General $1,000 49
2023 General $1,328 69
2022 General $631 39
2021 General $1,098 65
2020 General $947 64
2019 General $1,047 69

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ulrich Starke
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Ulrich Starke were reported at $14. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Ulrich Starke Internal Medicine median Middle half National median
2019 $1,047 $159 $48–$570 $163
2020 $947 $119 $33–$402 $114
2021 $1,098 $135 $37–$521 $132
2022 $631 $141 $42–$496 $149
2023 $1,328 $149 $45–$519 $160
2024 $1,000 $154 $47–$537 $164
2025 $14 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $804 45 payments
  2. Pfizer Inc. $628 36 payments
  3. AstraZeneca Pharmaceuticals LP $564 33 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $555 37 payments
  5. Lilly USA, LLC $553 30 payments
  6. Amgen Inc. $504 32 payments
  7. AbbVie, Inc. $376 21 payments
  8. Astellas Pharma US Inc $229 14 payments
  9. Kowa Pharmaceuticals America, Inc. $213 14 payments
  10. Abbott Laboratories $199 11 payments
  11. Other $1,442 83 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,065 356 payments
Products named General payments · program years 2019–2025
  1. RYBELSUS $496 31 payments
  2. Ozempic $490 31 payments
  3. Repatha $487 31 payments
  4. JARDIANCE Diabetes $463 32 payments
  5. FARXIGA $460 26 payments
  6. ELIQUIS $432 26 payments
  7. JARDIANCE Diabetes $302 17 payments
  8. UBRELVY $278 15 payments
  9. TRULICITY $278 15 payments
  10. AIMOVIG $254 15 payments
  11. Other $5,293 305 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 92 drugs

Part D claims

4,643

Median for Internal Medicine: 777

Drug cost

$332,351

Median for Internal Medicine: $73,373

Branded share of claims

17.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 57 $57,772
Mounjaro Tirzepatide Brand 36 $55,168
Rybelsus Semaglutide Brand 42 $50,825
Eliquis Apixaban Brand 38 $33,453
Ozempic Semaglutide Brand 29 $32,685
Januvia Sitagliptin Phosphate Brand 30 $26,300
Trulicity Dulaglutide Brand 13 $12,071
Myrbetriq Mirabegron Brand 19 $10,107
Farxiga Dapagliflozin Propanediol Brand 11 $7,208
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 25 $2,894

The 10 drugs with the highest cost, of 92 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$44,178

Of which drugs: $2,461

Medicare patients

193

Average age 75

Services billed

638

88 women, 105 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 47%
Arthritis 45%
Diabetes 26%
Atrial fibrillation 20%
Depression 20%
Chronic kidney disease 19%
Osteoporosis 12%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $107
$107 36 —
JARDIANCE
  • Lilly USA, LLC $68
  • Boehringer Ingelheim Pharmaceuticals, Inc. $34
$102 57 —
UBRELVY
  • AbbVie, Inc. $56
$56 — —
Qelbree
  • Supernus Pharmaceuticals, Inc. $52
$52 — —
QULIPTA
  • AbbVie, Inc. $37
$37 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

356 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record